nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyclothiazide—SLC12A1—urine—prostate cancer	0.0416	0.22	CbGeAlD
Methyclothiazide—SLC12A1—prostate gland—prostate cancer	0.0149	0.0789	CbGeAlD
Methyclothiazide—SLC12A3—renal system—prostate cancer	0.0133	0.0704	CbGeAlD
Methyclothiazide—SLC12A1—epithelium—prostate cancer	0.011	0.058	CbGeAlD
Methyclothiazide—SLC12A1—renal system—prostate cancer	0.0102	0.0538	CbGeAlD
Methyclothiazide—SLC12A1—urethra—prostate cancer	0.00999	0.0528	CbGeAlD
Methyclothiazide—Quinethazone—SLC12A2—prostate cancer	0.00868	1	CrCbGaD
Methyclothiazide—CA4—prostate gland—prostate cancer	0.00803	0.0424	CbGeAlD
Methyclothiazide—CA1—renal system—prostate cancer	0.007	0.037	CbGeAlD
Methyclothiazide—CA4—seminal vesicle—prostate cancer	0.00679	0.0359	CbGeAlD
Methyclothiazide—CA2—prostate gland—prostate cancer	0.00665	0.0352	CbGeAlD
Methyclothiazide—SLC12A1—testis—prostate cancer	0.00657	0.0347	CbGeAlD
Methyclothiazide—CA2—seminal vesicle—prostate cancer	0.00563	0.0298	CbGeAlD
Methyclothiazide—CA4—renal system—prostate cancer	0.00547	0.0289	CbGeAlD
Methyclothiazide—CA4—urethra—prostate cancer	0.00537	0.0284	CbGeAlD
Methyclothiazide—CA1—bone marrow—prostate cancer	0.00529	0.028	CbGeAlD
Methyclothiazide—CA2—epithelium—prostate cancer	0.00489	0.0258	CbGeAlD
Methyclothiazide—CA2—renal system—prostate cancer	0.00454	0.024	CbGeAlD
Methyclothiazide—CA4—bone marrow—prostate cancer	0.00414	0.0219	CbGeAlD
Methyclothiazide—CA4—testis—prostate cancer	0.00354	0.0187	CbGeAlD
Methyclothiazide—CA2—bone marrow—prostate cancer	0.00343	0.0181	CbGeAlD
Methyclothiazide—CA1—lymph node—prostate cancer	0.00328	0.0173	CbGeAlD
Methyclothiazide—CA2—testis—prostate cancer	0.00293	0.0155	CbGeAlD
Methyclothiazide—CA4—lymph node—prostate cancer	0.00256	0.0135	CbGeAlD
Methyclothiazide—CA2—lymph node—prostate cancer	0.00212	0.0112	CbGeAlD
Methyclothiazide—Purpura—Prednisone—prostate cancer	0.00107	0.00173	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Capecitabine—prostate cancer	0.00106	0.00171	CcSEcCtD
Methyclothiazide—Vomiting—Bicalutamide—prostate cancer	0.00105	0.0017	CcSEcCtD
Methyclothiazide—Blood uric acid increased—Doxorubicin—prostate cancer	0.00105	0.00169	CcSEcCtD
Methyclothiazide—Rash—Bicalutamide—prostate cancer	0.00105	0.00169	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Epirubicin—prostate cancer	0.00105	0.00169	CcSEcCtD
Methyclothiazide—Dermatitis—Bicalutamide—prostate cancer	0.00104	0.00169	CcSEcCtD
Methyclothiazide—Headache—Bicalutamide—prostate cancer	0.00104	0.00168	CcSEcCtD
Methyclothiazide—Agranulocytosis—Etoposide—prostate cancer	0.00104	0.00167	CcSEcCtD
Methyclothiazide—Paraesthesia—Goserelin—prostate cancer	0.00104	0.00167	CcSEcCtD
Methyclothiazide—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00103	0.00167	CcSEcCtD
Methyclothiazide—Agitation—Estradiol—prostate cancer	0.00103	0.00166	CcSEcCtD
Methyclothiazide—Paraesthesia—Conjugated Estrogens—prostate cancer	0.00103	0.00166	CcSEcCtD
Methyclothiazide—Vertigo—Estradiol—prostate cancer	0.00101	0.00163	CcSEcCtD
Methyclothiazide—Asthenia—Ethinyl Estradiol—prostate cancer	0.00101	0.00162	CcSEcCtD
Methyclothiazide—Decreased appetite—Goserelin—prostate cancer	0.001	0.00162	CcSEcCtD
Methyclothiazide—Decreased appetite—Conjugated Estrogens—prostate cancer	0.000993	0.0016	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Epirubicin—prostate cancer	0.000991	0.0016	CcSEcCtD
Methyclothiazide—Constipation—Goserelin—prostate cancer	0.000986	0.00159	CcSEcCtD
Methyclothiazide—Nausea—Bicalutamide—prostate cancer	0.000985	0.00159	CcSEcCtD
Methyclothiazide—Vision blurred—Mitoxantrone—prostate cancer	0.000984	0.00159	CcSEcCtD
Methyclothiazide—Constipation—Conjugated Estrogens—prostate cancer	0.000977	0.00158	CcSEcCtD
Methyclothiazide—Aplastic anaemia—Doxorubicin—prostate cancer	0.000967	0.00156	CcSEcCtD
Methyclothiazide—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000959	0.00155	CcSEcCtD
Methyclothiazide—Erythema multiforme—Etoposide—prostate cancer	0.000943	0.00152	CcSEcCtD
Methyclothiazide—Leukopenia—Mitoxantrone—prostate cancer	0.000934	0.00151	CcSEcCtD
Methyclothiazide—Pneumonia—Docetaxel—prostate cancer	0.000929	0.0015	CcSEcCtD
Methyclothiazide—Dizziness—Ethinyl Estradiol—prostate cancer	0.000927	0.0015	CcSEcCtD
Methyclothiazide—Photosensitivity—Epirubicin—prostate cancer	0.00092	0.00149	CcSEcCtD
Methyclothiazide—Pulmonary oedema—Doxorubicin—prostate cancer	0.000917	0.00148	CcSEcCtD
Methyclothiazide—Urticaria—Goserelin—prostate cancer	0.000916	0.00148	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Docetaxel—prostate cancer	0.000915	0.00148	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Capecitabine—prostate cancer	0.000915	0.00148	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Estradiol—prostate cancer	0.000914	0.00148	CcSEcCtD
Methyclothiazide—Body temperature increased—Goserelin—prostate cancer	0.000912	0.00147	CcSEcCtD
Methyclothiazide—Urticaria—Conjugated Estrogens—prostate cancer	0.000907	0.00147	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Capecitabine—prostate cancer	0.000904	0.00146	CcSEcCtD
Methyclothiazide—Vascular purpura—Epirubicin—prostate cancer	0.000903	0.00146	CcSEcCtD
Methyclothiazide—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000903	0.00146	CcSEcCtD
Methyclothiazide—Jaundice—Docetaxel—prostate cancer	0.0009	0.00145	CcSEcCtD
Methyclothiazide—Pneumonia—Capecitabine—prostate cancer	0.000899	0.00145	CcSEcCtD
Methyclothiazide—Vomiting—Ethinyl Estradiol—prostate cancer	0.000891	0.00144	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Capecitabine—prostate cancer	0.000886	0.00143	CcSEcCtD
Methyclothiazide—Rash—Ethinyl Estradiol—prostate cancer	0.000883	0.00143	CcSEcCtD
Methyclothiazide—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000883	0.00143	CcSEcCtD
Methyclothiazide—Headache—Ethinyl Estradiol—prostate cancer	0.000878	0.00142	CcSEcCtD
Methyclothiazide—Pancreatitis—Prednisone—prostate cancer	0.000876	0.00141	CcSEcCtD
Methyclothiazide—Jaundice—Capecitabine—prostate cancer	0.000871	0.00141	CcSEcCtD
Methyclothiazide—Agranulocytosis—Docetaxel—prostate cancer	0.000862	0.00139	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Mitoxantrone—prostate cancer	0.000852	0.00138	CcSEcCtD
Methyclothiazide—Photosensitivity—Doxorubicin—prostate cancer	0.000852	0.00138	CcSEcCtD
Methyclothiazide—Hypersensitivity—Goserelin—prostate cancer	0.00085	0.00137	CcSEcCtD
Methyclothiazide—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000842	0.00136	CcSEcCtD
Methyclothiazide—Purpura—Epirubicin—prostate cancer	0.000838	0.00135	CcSEcCtD
Methyclothiazide—Vascular purpura—Doxorubicin—prostate cancer	0.000836	0.00135	CcSEcCtD
Methyclothiazide—Muscle spasms—Etoposide—prostate cancer	0.000835	0.00135	CcSEcCtD
Methyclothiazide—Agranulocytosis—Capecitabine—prostate cancer	0.000834	0.00135	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Mitoxantrone—prostate cancer	0.000834	0.00135	CcSEcCtD
Methyclothiazide—Nausea—Ethinyl Estradiol—prostate cancer	0.000832	0.00134	CcSEcCtD
Methyclothiazide—Asthenia—Goserelin—prostate cancer	0.000827	0.00134	CcSEcCtD
Methyclothiazide—Paraesthesia—Estradiol—prostate cancer	0.000821	0.00133	CcSEcCtD
Methyclothiazide—Asthenia—Conjugated Estrogens—prostate cancer	0.00082	0.00132	CcSEcCtD
Methyclothiazide—Anorexia—Mitoxantrone—prostate cancer	0.000812	0.00131	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Prednisone—prostate cancer	0.000806	0.0013	CcSEcCtD
Methyclothiazide—Decreased appetite—Estradiol—prostate cancer	0.000795	0.00128	CcSEcCtD
Methyclothiazide—Diarrhoea—Goserelin—prostate cancer	0.000789	0.00127	CcSEcCtD
Methyclothiazide—Erythema multiforme—Docetaxel—prostate cancer	0.000784	0.00127	CcSEcCtD
Methyclothiazide—Constipation—Estradiol—prostate cancer	0.000782	0.00126	CcSEcCtD
Methyclothiazide—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000782	0.00126	CcSEcCtD
Methyclothiazide—Vertigo—Etoposide—prostate cancer	0.00078	0.00126	CcSEcCtD
Methyclothiazide—Leukopenia—Etoposide—prostate cancer	0.000777	0.00126	CcSEcCtD
Methyclothiazide—Purpura—Doxorubicin—prostate cancer	0.000776	0.00125	CcSEcCtD
Methyclothiazide—Paraesthesia—Mitoxantrone—prostate cancer	0.000765	0.00124	CcSEcCtD
Methyclothiazide—Dizziness—Goserelin—prostate cancer	0.000763	0.00123	CcSEcCtD
Methyclothiazide—Erythema multiforme—Capecitabine—prostate cancer	0.000759	0.00123	CcSEcCtD
Methyclothiazide—Dizziness—Conjugated Estrogens—prostate cancer	0.000755	0.00122	CcSEcCtD
Methyclothiazide—Decreased appetite—Mitoxantrone—prostate cancer	0.00074	0.0012	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Epirubicin—prostate cancer	0.000738	0.00119	CcSEcCtD
Methyclothiazide—Vomiting—Goserelin—prostate cancer	0.000733	0.00118	CcSEcCtD
Methyclothiazide—Constipation—Mitoxantrone—prostate cancer	0.000728	0.00118	CcSEcCtD
Methyclothiazide—Rash—Goserelin—prostate cancer	0.000727	0.00117	CcSEcCtD
Methyclothiazide—Dermatitis—Goserelin—prostate cancer	0.000726	0.00117	CcSEcCtD
Methyclothiazide—Vomiting—Conjugated Estrogens—prostate cancer	0.000726	0.00117	CcSEcCtD
Methyclothiazide—Urticaria—Estradiol—prostate cancer	0.000726	0.00117	CcSEcCtD
Methyclothiazide—Body temperature increased—Estradiol—prostate cancer	0.000723	0.00117	CcSEcCtD
Methyclothiazide—Headache—Goserelin—prostate cancer	0.000722	0.00117	CcSEcCtD
Methyclothiazide—Malnutrition—Docetaxel—prostate cancer	0.000721	0.00117	CcSEcCtD
Methyclothiazide—Rash—Conjugated Estrogens—prostate cancer	0.00072	0.00116	CcSEcCtD
Methyclothiazide—Dermatitis—Conjugated Estrogens—prostate cancer	0.00072	0.00116	CcSEcCtD
Methyclothiazide—Headache—Conjugated Estrogens—prostate cancer	0.000716	0.00116	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Etoposide—prostate cancer	0.000709	0.00114	CcSEcCtD
Methyclothiazide—Malnutrition—Capecitabine—prostate cancer	0.000699	0.00113	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Etoposide—prostate cancer	0.000694	0.00112	CcSEcCtD
Methyclothiazide—Muscle spasms—Docetaxel—prostate cancer	0.000694	0.00112	CcSEcCtD
Methyclothiazide—Nausea—Goserelin—prostate cancer	0.000685	0.00111	CcSEcCtD
Methyclothiazide—Pancreatitis—Epirubicin—prostate cancer	0.000685	0.00111	CcSEcCtD
Methyclothiazide—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000683	0.0011	CcSEcCtD
Methyclothiazide—Nausea—Conjugated Estrogens—prostate cancer	0.000678	0.0011	CcSEcCtD
Methyclothiazide—Urticaria—Mitoxantrone—prostate cancer	0.000677	0.00109	CcSEcCtD
Methyclothiazide—Anorexia—Etoposide—prostate cancer	0.000675	0.00109	CcSEcCtD
Methyclothiazide—Hypersensitivity—Estradiol—prostate cancer	0.000674	0.00109	CcSEcCtD
Methyclothiazide—Body temperature increased—Mitoxantrone—prostate cancer	0.000673	0.00109	CcSEcCtD
Methyclothiazide—Muscle spasms—Capecitabine—prostate cancer	0.000672	0.00108	CcSEcCtD
Methyclothiazide—Vision blurred—Capecitabine—prostate cancer	0.000658	0.00106	CcSEcCtD
Methyclothiazide—Asthenia—Estradiol—prostate cancer	0.000656	0.00106	CcSEcCtD
Methyclothiazide—Leukopenia—Docetaxel—prostate cancer	0.000646	0.00104	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Epirubicin—prostate cancer	0.000638	0.00103	CcSEcCtD
Methyclothiazide—Paraesthesia—Etoposide—prostate cancer	0.000636	0.00103	CcSEcCtD
Methyclothiazide—Pancreatitis—Doxorubicin—prostate cancer	0.000634	0.00102	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Epirubicin—prostate cancer	0.00063	0.00102	CcSEcCtD
Methyclothiazide—Vertigo—Capecitabine—prostate cancer	0.000628	0.00101	CcSEcCtD
Methyclothiazide—Hypersensitivity—Mitoxantrone—prostate cancer	0.000628	0.00101	CcSEcCtD
Methyclothiazide—Pneumonia—Epirubicin—prostate cancer	0.000626	0.00101	CcSEcCtD
Methyclothiazide—Diarrhoea—Estradiol—prostate cancer	0.000626	0.00101	CcSEcCtD
Methyclothiazide—Leukopenia—Capecitabine—prostate cancer	0.000625	0.00101	CcSEcCtD
Methyclothiazide—Malnutrition—Prednisone—prostate cancer	0.000622	0.00101	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000617	0.000997	CcSEcCtD
Methyclothiazide—Decreased appetite—Etoposide—prostate cancer	0.000616	0.000995	CcSEcCtD
Methyclothiazide—Asthenia—Mitoxantrone—prostate cancer	0.000611	0.000987	CcSEcCtD
Methyclothiazide—Jaundice—Epirubicin—prostate cancer	0.000607	0.00098	CcSEcCtD
Methyclothiazide—Constipation—Etoposide—prostate cancer	0.000606	0.000979	CcSEcCtD
Methyclothiazide—Dizziness—Estradiol—prostate cancer	0.000605	0.000976	CcSEcCtD
Methyclothiazide—Photosensitivity reaction—Doxorubicin—prostate cancer	0.00059	0.000953	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Docetaxel—prostate cancer	0.000589	0.000951	CcSEcCtD
Methyclothiazide—Vision blurred—Prednisone—prostate cancer	0.000586	0.000947	CcSEcCtD
Methyclothiazide—Hyperglycaemia—Doxorubicin—prostate cancer	0.000583	0.000942	CcSEcCtD
Methyclothiazide—Diarrhoea—Mitoxantrone—prostate cancer	0.000583	0.000941	CcSEcCtD
Methyclothiazide—Vomiting—Estradiol—prostate cancer	0.000581	0.000939	CcSEcCtD
Methyclothiazide—Agranulocytosis—Epirubicin—prostate cancer	0.000581	0.000939	CcSEcCtD
Methyclothiazide—Pneumonia—Doxorubicin—prostate cancer	0.00058	0.000936	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Docetaxel—prostate cancer	0.000577	0.000931	CcSEcCtD
Methyclothiazide—Rash—Estradiol—prostate cancer	0.000576	0.000931	CcSEcCtD
Methyclothiazide—Dermatitis—Estradiol—prostate cancer	0.000576	0.00093	CcSEcCtD
Methyclothiazide—Headache—Estradiol—prostate cancer	0.000573	0.000925	CcSEcCtD
Methyclothiazide—Agitation—Prednisone—prostate cancer	0.000572	0.000924	CcSEcCtD
Methyclothiazide—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	0.000571	0.000923	CcSEcCtD
Methyclothiazide—Urticaria—Etoposide—prostate cancer	0.000563	0.000909	CcSEcCtD
Methyclothiazide—Jaundice—Doxorubicin—prostate cancer	0.000562	0.000907	CcSEcCtD
Methyclothiazide—Anorexia—Docetaxel—prostate cancer	0.000561	0.000907	CcSEcCtD
Methyclothiazide—Body temperature increased—Etoposide—prostate cancer	0.00056	0.000905	CcSEcCtD
Methyclothiazide—Vertigo—Prednisone—prostate cancer	0.000559	0.000903	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Capecitabine—prostate cancer	0.000558	0.000902	CcSEcCtD
Methyclothiazide—Anorexia—Capecitabine—prostate cancer	0.000543	0.000878	CcSEcCtD
Methyclothiazide—Nausea—Estradiol—prostate cancer	0.000543	0.000877	CcSEcCtD
Methyclothiazide—Vomiting—Mitoxantrone—prostate cancer	0.000542	0.000875	CcSEcCtD
Methyclothiazide—Agranulocytosis—Doxorubicin—prostate cancer	0.000538	0.000869	CcSEcCtD
Methyclothiazide—Rash—Mitoxantrone—prostate cancer	0.000537	0.000867	CcSEcCtD
Methyclothiazide—Dermatitis—Mitoxantrone—prostate cancer	0.000537	0.000867	CcSEcCtD
Methyclothiazide—Headache—Mitoxantrone—prostate cancer	0.000534	0.000862	CcSEcCtD
Methyclothiazide—Paraesthesia—Docetaxel—prostate cancer	0.000529	0.000854	CcSEcCtD
Methyclothiazide—Erythema multiforme—Epirubicin—prostate cancer	0.000529	0.000854	CcSEcCtD
Methyclothiazide—Hypersensitivity—Etoposide—prostate cancer	0.000522	0.000843	CcSEcCtD
Methyclothiazide—Paraesthesia—Capecitabine—prostate cancer	0.000512	0.000827	CcSEcCtD
Methyclothiazide—Decreased appetite—Docetaxel—prostate cancer	0.000512	0.000827	CcSEcCtD
Methyclothiazide—Asthenia—Etoposide—prostate cancer	0.000508	0.000821	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Prednisone—prostate cancer	0.000508	0.00082	CcSEcCtD
Methyclothiazide—Nausea—Mitoxantrone—prostate cancer	0.000506	0.000817	CcSEcCtD
Methyclothiazide—Constipation—Docetaxel—prostate cancer	0.000504	0.000813	CcSEcCtD
Methyclothiazide—Decreased appetite—Capecitabine—prostate cancer	0.000496	0.0008	CcSEcCtD
Methyclothiazide—Erythema multiforme—Doxorubicin—prostate cancer	0.000489	0.00079	CcSEcCtD
Methyclothiazide—Constipation—Capecitabine—prostate cancer	0.000488	0.000787	CcSEcCtD
Methyclothiazide—Malnutrition—Epirubicin—prostate cancer	0.000487	0.000786	CcSEcCtD
Methyclothiazide—Diarrhoea—Etoposide—prostate cancer	0.000485	0.000783	CcSEcCtD
Methyclothiazide—Anorexia—Prednisone—prostate cancer	0.000484	0.000782	CcSEcCtD
Methyclothiazide—Dizziness—Etoposide—prostate cancer	0.000469	0.000757	CcSEcCtD
Methyclothiazide—Muscle spasms—Epirubicin—prostate cancer	0.000468	0.000756	CcSEcCtD
Methyclothiazide—Body temperature increased—Docetaxel—prostate cancer	0.000465	0.000752	CcSEcCtD
Methyclothiazide—Vision blurred—Epirubicin—prostate cancer	0.000459	0.000741	CcSEcCtD
Methyclothiazide—Paraesthesia—Prednisone—prostate cancer	0.000456	0.000737	CcSEcCtD
Methyclothiazide—Urticaria—Capecitabine—prostate cancer	0.000453	0.000732	CcSEcCtD
Methyclothiazide—Body temperature increased—Capecitabine—prostate cancer	0.000451	0.000728	CcSEcCtD
Methyclothiazide—Vomiting—Etoposide—prostate cancer	0.00045	0.000728	CcSEcCtD
Methyclothiazide—Malnutrition—Doxorubicin—prostate cancer	0.00045	0.000727	CcSEcCtD
Methyclothiazide—Agitation—Epirubicin—prostate cancer	0.000447	0.000722	CcSEcCtD
Methyclothiazide—Rash—Etoposide—prostate cancer	0.000447	0.000722	CcSEcCtD
Methyclothiazide—Dermatitis—Etoposide—prostate cancer	0.000446	0.000721	CcSEcCtD
Methyclothiazide—Headache—Etoposide—prostate cancer	0.000444	0.000717	CcSEcCtD
Methyclothiazide—Decreased appetite—Prednisone—prostate cancer	0.000441	0.000713	CcSEcCtD
Methyclothiazide—Vertigo—Epirubicin—prostate cancer	0.000437	0.000706	CcSEcCtD
Methyclothiazide—Leukopenia—Epirubicin—prostate cancer	0.000436	0.000704	CcSEcCtD
Methyclothiazide—Constipation—Prednisone—prostate cancer	0.000434	0.000701	CcSEcCtD
Methyclothiazide—Hypersensitivity—Docetaxel—prostate cancer	0.000434	0.000701	CcSEcCtD
Methyclothiazide—Muscle spasms—Doxorubicin—prostate cancer	0.000433	0.000699	CcSEcCtD
Methyclothiazide—Vision blurred—Doxorubicin—prostate cancer	0.000424	0.000685	CcSEcCtD
Methyclothiazide—Asthenia—Docetaxel—prostate cancer	0.000422	0.000682	CcSEcCtD
Methyclothiazide—Nausea—Etoposide—prostate cancer	0.000421	0.00068	CcSEcCtD
Methyclothiazide—Hypersensitivity—Capecitabine—prostate cancer	0.00042	0.000678	CcSEcCtD
Methyclothiazide—Agitation—Doxorubicin—prostate cancer	0.000414	0.000668	CcSEcCtD
Methyclothiazide—Asthenia—Capecitabine—prostate cancer	0.000409	0.000661	CcSEcCtD
Methyclothiazide—Vertigo—Doxorubicin—prostate cancer	0.000405	0.000653	CcSEcCtD
Methyclothiazide—Urticaria—Prednisone—prostate cancer	0.000403	0.000652	CcSEcCtD
Methyclothiazide—Leukopenia—Doxorubicin—prostate cancer	0.000403	0.000651	CcSEcCtD
Methyclothiazide—Diarrhoea—Docetaxel—prostate cancer	0.000403	0.000651	CcSEcCtD
Methyclothiazide—Body temperature increased—Prednisone—prostate cancer	0.000401	0.000648	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Epirubicin—prostate cancer	0.000397	0.000642	CcSEcCtD
Methyclothiazide—Diarrhoea—Capecitabine—prostate cancer	0.00039	0.00063	CcSEcCtD
Methyclothiazide—Dizziness—Docetaxel—prostate cancer	0.000389	0.000629	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Epirubicin—prostate cancer	0.000389	0.000628	CcSEcCtD
Methyclothiazide—Anorexia—Epirubicin—prostate cancer	0.000379	0.000611	CcSEcCtD
Methyclothiazide—Dizziness—Capecitabine—prostate cancer	0.000377	0.000609	CcSEcCtD
Methyclothiazide—Vomiting—Docetaxel—prostate cancer	0.000374	0.000605	CcSEcCtD
Methyclothiazide—Hypersensitivity—Prednisone—prostate cancer	0.000374	0.000604	CcSEcCtD
Methyclothiazide—Rash—Docetaxel—prostate cancer	0.000371	0.0006	CcSEcCtD
Methyclothiazide—Dermatitis—Docetaxel—prostate cancer	0.000371	0.000599	CcSEcCtD
Methyclothiazide—Headache—Docetaxel—prostate cancer	0.000369	0.000596	CcSEcCtD
Methyclothiazide—Anaphylactic shock—Doxorubicin—prostate cancer	0.000367	0.000594	CcSEcCtD
Methyclothiazide—Asthenia—Prednisone—prostate cancer	0.000364	0.000588	CcSEcCtD
Methyclothiazide—Vomiting—Capecitabine—prostate cancer	0.000362	0.000585	CcSEcCtD
Methyclothiazide—Thrombocytopenia—Doxorubicin—prostate cancer	0.00036	0.000581	CcSEcCtD
Methyclothiazide—Rash—Capecitabine—prostate cancer	0.000359	0.000581	CcSEcCtD
Methyclothiazide—Dermatitis—Capecitabine—prostate cancer	0.000359	0.00058	CcSEcCtD
Methyclothiazide—Headache—Capecitabine—prostate cancer	0.000357	0.000577	CcSEcCtD
Methyclothiazide—Paraesthesia—Epirubicin—prostate cancer	0.000357	0.000576	CcSEcCtD
Methyclothiazide—Anorexia—Doxorubicin—prostate cancer	0.00035	0.000566	CcSEcCtD
Methyclothiazide—Nausea—Docetaxel—prostate cancer	0.00035	0.000565	CcSEcCtD
Methyclothiazide—Diarrhoea—Prednisone—prostate cancer	0.000347	0.000561	CcSEcCtD
Methyclothiazide—Decreased appetite—Epirubicin—prostate cancer	0.000345	0.000558	CcSEcCtD
Methyclothiazide—Constipation—Epirubicin—prostate cancer	0.00034	0.000549	CcSEcCtD
Methyclothiazide—Nausea—Capecitabine—prostate cancer	0.000339	0.000547	CcSEcCtD
Methyclothiazide—Dizziness—Prednisone—prostate cancer	0.000336	0.000542	CcSEcCtD
Methyclothiazide—Paraesthesia—Doxorubicin—prostate cancer	0.00033	0.000533	CcSEcCtD
Methyclothiazide—Vomiting—Prednisone—prostate cancer	0.000323	0.000522	CcSEcCtD
Methyclothiazide—Rash—Prednisone—prostate cancer	0.00032	0.000517	CcSEcCtD
Methyclothiazide—Dermatitis—Prednisone—prostate cancer	0.00032	0.000517	CcSEcCtD
Methyclothiazide—Decreased appetite—Doxorubicin—prostate cancer	0.000319	0.000516	CcSEcCtD
Methyclothiazide—Headache—Prednisone—prostate cancer	0.000318	0.000514	CcSEcCtD
Methyclothiazide—Urticaria—Epirubicin—prostate cancer	0.000316	0.00051	CcSEcCtD
Methyclothiazide—Constipation—Doxorubicin—prostate cancer	0.000314	0.000508	CcSEcCtD
Methyclothiazide—Body temperature increased—Epirubicin—prostate cancer	0.000314	0.000507	CcSEcCtD
Methyclothiazide—CA1—Metabolism—DEGS1—prostate cancer	0.000312	0.0017	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NAT1—prostate cancer	0.000312	0.0017	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—HSD17B1—prostate cancer	0.00031	0.00169	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—SLC5A5—prostate cancer	0.000307	0.00168	CbGpPWpGaD
Methyclothiazide—Nausea—Prednisone—prostate cancer	0.000302	0.000487	CcSEcCtD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000298	0.00163	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—HSD17B1—prostate cancer	0.000297	0.00162	CbGpPWpGaD
Methyclothiazide—Hypersensitivity—Epirubicin—prostate cancer	0.000293	0.000473	CcSEcCtD
Methyclothiazide—Urticaria—Doxorubicin—prostate cancer	0.000292	0.000472	CcSEcCtD
Methyclothiazide—Body temperature increased—Doxorubicin—prostate cancer	0.000291	0.000469	CcSEcCtD
Methyclothiazide—CA4—Metabolism—B4GALT4—prostate cancer	0.000288	0.00158	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—HPGD—prostate cancer	0.000288	0.00158	CbGpPWpGaD
Methyclothiazide—Asthenia—Epirubicin—prostate cancer	0.000285	0.00046	CcSEcCtD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000284	0.00155	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—B4GALT4—prostate cancer	0.000276	0.00151	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—HPGD—prostate cancer	0.000276	0.00151	CbGpPWpGaD
Methyclothiazide—Diarrhoea—Epirubicin—prostate cancer	0.000272	0.000439	CcSEcCtD
Methyclothiazide—CA4—Metabolism—TNFRSF21—prostate cancer	0.000271	0.00148	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—NCOA1—prostate cancer	0.000271	0.00148	CbGpPWpGaD
Methyclothiazide—Hypersensitivity—Doxorubicin—prostate cancer	0.000271	0.000437	CcSEcCtD
Methyclothiazide—CA1—Metabolism—B4GALT4—prostate cancer	0.000265	0.00145	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—HPGD—prostate cancer	0.000265	0.00145	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP7B1—prostate cancer	0.000264	0.00144	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—MTAP—prostate cancer	0.000264	0.00144	CbGpPWpGaD
Methyclothiazide—Asthenia—Doxorubicin—prostate cancer	0.000264	0.000426	CcSEcCtD
Methyclothiazide—Dizziness—Epirubicin—prostate cancer	0.000263	0.000424	CcSEcCtD
Methyclothiazide—CA2—Metabolism—TNFRSF21—prostate cancer	0.00026	0.00142	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—RXRA—prostate cancer	0.000258	0.00141	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SULT1E1—prostate cancer	0.000257	0.0014	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SRD5A1—prostate cancer	0.000257	0.0014	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP7B1—prostate cancer	0.000253	0.00138	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—MTAP—prostate cancer	0.000253	0.00138	CbGpPWpGaD
Methyclothiazide—Vomiting—Epirubicin—prostate cancer	0.000253	0.000408	CcSEcCtD
Methyclothiazide—Diarrhoea—Doxorubicin—prostate cancer	0.000251	0.000406	CcSEcCtD
Methyclothiazide—Rash—Epirubicin—prostate cancer	0.00025	0.000404	CcSEcCtD
Methyclothiazide—Dermatitis—Epirubicin—prostate cancer	0.00025	0.000404	CcSEcCtD
Methyclothiazide—CA1—Metabolism—TNFRSF21—prostate cancer	0.000249	0.00136	CbGpPWpGaD
Methyclothiazide—Headache—Epirubicin—prostate cancer	0.000249	0.000402	CcSEcCtD
Methyclothiazide—CA2—Metabolism—SRD5A1—prostate cancer	0.000246	0.00135	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SULT1E1—prostate cancer	0.000246	0.00135	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ACSL4—prostate cancer	0.000245	0.00134	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—HSD17B3—prostate cancer	0.000245	0.00134	CbGpPWpGaD
Methyclothiazide—Dizziness—Doxorubicin—prostate cancer	0.000243	0.000393	CcSEcCtD
Methyclothiazide—CA1—Metabolism—CYP7B1—prostate cancer	0.000242	0.00132	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—MTAP—prostate cancer	0.000242	0.00132	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SULT1E1—prostate cancer	0.000236	0.00129	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SRD5A1—prostate cancer	0.000236	0.00129	CbGpPWpGaD
Methyclothiazide—Nausea—Epirubicin—prostate cancer	0.000236	0.000381	CcSEcCtD
Methyclothiazide—CA2—Metabolism—ACSL4—prostate cancer	0.000235	0.00128	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—HSD17B3—prostate cancer	0.000235	0.00128	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ARG2—prostate cancer	0.000235	0.00128	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PHGDH—prostate cancer	0.000235	0.00128	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—UMPS—prostate cancer	0.000235	0.00128	CbGpPWpGaD
Methyclothiazide—Vomiting—Doxorubicin—prostate cancer	0.000234	0.000377	CcSEcCtD
Methyclothiazide—Rash—Doxorubicin—prostate cancer	0.000232	0.000374	CcSEcCtD
Methyclothiazide—Dermatitis—Doxorubicin—prostate cancer	0.000231	0.000374	CcSEcCtD
Methyclothiazide—CA4—Metabolism—LDHB—prostate cancer	0.00023	0.00126	CbGpPWpGaD
Methyclothiazide—Headache—Doxorubicin—prostate cancer	0.00023	0.000372	CcSEcCtD
Methyclothiazide—CA4—Metabolism—CYP3A5—prostate cancer	0.000226	0.00124	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PHGDH—prostate cancer	0.000225	0.00123	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ARG2—prostate cancer	0.000225	0.00123	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—UMPS—prostate cancer	0.000225	0.00123	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ACSL4—prostate cancer	0.000225	0.00123	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—HSD17B3—prostate cancer	0.000225	0.00123	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—LDHB—prostate cancer	0.000221	0.00121	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PDHA1—prostate cancer	0.000219	0.00119	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTA3—prostate cancer	0.000219	0.00119	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—UCP3—prostate cancer	0.000219	0.00119	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—TCN2—prostate cancer	0.000219	0.00119	CbGpPWpGaD
Methyclothiazide—Nausea—Doxorubicin—prostate cancer	0.000218	0.000353	CcSEcCtD
Methyclothiazide—CA2—Metabolism—CYP3A5—prostate cancer	0.000217	0.00119	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000217	0.00118	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ARG2—prostate cancer	0.000216	0.00118	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PHGDH—prostate cancer	0.000216	0.00118	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—UMPS—prostate cancer	0.000216	0.00118	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—LDHB—prostate cancer	0.000212	0.00116	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PDHA1—prostate cancer	0.000209	0.00114	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTA3—prostate cancer	0.000209	0.00114	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—UCP3—prostate cancer	0.000209	0.00114	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—TCN2—prostate cancer	0.000209	0.00114	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—HSD3B1—prostate cancer	0.000208	0.00114	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SLC22A3—prostate cancer	0.000208	0.00114	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP3A5—prostate cancer	0.000208	0.00114	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PDHA1—prostate cancer	0.000201	0.0011	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTA3—prostate cancer	0.000201	0.0011	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—UCP3—prostate cancer	0.000201	0.0011	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—TCN2—prostate cancer	0.000201	0.0011	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SLC22A3—prostate cancer	0.0002	0.00109	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—HSD3B1—prostate cancer	0.0002	0.00109	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—TBXAS1—prostate cancer	0.0002	0.00109	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTA4—prostate cancer	0.0002	0.00109	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—PPARA—prostate cancer	0.000197	0.00108	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTA2—prostate cancer	0.000195	0.00106	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SULT1A1—prostate cancer	0.000192	0.00105	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ABCG5—prostate cancer	0.000192	0.00105	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—TBXAS1—prostate cancer	0.000192	0.00105	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—HSD3B1—prostate cancer	0.000192	0.00105	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SLC22A3—prostate cancer	0.000192	0.00105	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTA4—prostate cancer	0.000192	0.00105	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTA1—prostate cancer	0.000188	0.00103	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTA2—prostate cancer	0.000187	0.00102	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—HSD3B2—prostate cancer	0.000186	0.00102	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—NAT2—prostate cancer	0.000186	0.00102	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTO1—prostate cancer	0.000186	0.00102	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ABCG5—prostate cancer	0.000184	0.00101	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SULT1A1—prostate cancer	0.000184	0.00101	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTA4—prostate cancer	0.000184	0.001	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—TBXAS1—prostate cancer	0.000184	0.001	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTA1—prostate cancer	0.00018	0.000984	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTA2—prostate cancer	0.000179	0.000978	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTO1—prostate cancer	0.000178	0.000973	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—NAT2—prostate cancer	0.000178	0.000973	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—HSD3B2—prostate cancer	0.000178	0.000973	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PLCB2—prostate cancer	0.000178	0.000973	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP2C18—prostate cancer	0.000178	0.000973	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—LRP2—prostate cancer	0.000178	0.000973	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ABCG5—prostate cancer	0.000177	0.000966	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SULT1A1—prostate cancer	0.000177	0.000966	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—P4HB—prostate cancer	0.000175	0.000954	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTA1—prostate cancer	0.000173	0.000944	CbGpPWpGaD
Methyclothiazide—SLC12A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	0.000172	0.000941	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PLCB2—prostate cancer	0.000171	0.000933	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP2C18—prostate cancer	0.000171	0.000933	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—LRP2—prostate cancer	0.000171	0.000933	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTO1—prostate cancer	0.000171	0.000933	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—HSD3B2—prostate cancer	0.000171	0.000933	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NAT2—prostate cancer	0.000171	0.000933	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SLC22A1—prostate cancer	0.00017	0.000928	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—P4HB—prostate cancer	0.000167	0.000915	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SULT2A1—prostate cancer	0.000166	0.000905	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PLCB2—prostate cancer	0.000164	0.000895	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—LRP2—prostate cancer	0.000164	0.000895	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP2C18—prostate cancer	0.000164	0.000895	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SLC22A1—prostate cancer	0.000163	0.00089	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—MED12—prostate cancer	0.000163	0.00089	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GNG5—prostate cancer	0.000162	0.000883	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—P4HB—prostate cancer	0.000161	0.000877	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SULT2A1—prostate cancer	0.000159	0.000867	CbGpPWpGaD
Methyclothiazide—SLC12A3—Transmembrane transport of small molecules—CREBBP—prostate cancer	0.000156	0.000854	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SLC22A1—prostate cancer	0.000156	0.000853	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—MED12—prostate cancer	0.000156	0.000853	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—NCOA3—prostate cancer	0.000156	0.000851	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GNG5—prostate cancer	0.000155	0.000847	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SULT2A1—prostate cancer	0.000152	0.000832	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—MED12—prostate cancer	0.00015	0.000818	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—NCOA3—prostate cancer	0.000149	0.000816	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GNG5—prostate cancer	0.000149	0.000812	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—HPGDS—prostate cancer	0.000149	0.000812	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP2C19—prostate cancer	0.000148	0.000806	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTT1—prostate cancer	0.000144	0.000787	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ACHE—prostate cancer	0.000144	0.000787	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NCOA3—prostate cancer	0.000143	0.000782	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—HPGDS—prostate cancer	0.000142	0.000778	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP2A6—prostate cancer	0.000142	0.000778	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP2C19—prostate cancer	0.000142	0.000773	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—AKR1C3—prostate cancer	0.000139	0.000757	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ACHE—prostate cancer	0.000138	0.000755	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTT1—prostate cancer	0.000138	0.000755	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PRKACB—prostate cancer	0.000138	0.000753	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—HPGDS—prostate cancer	0.000137	0.000746	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP2A6—prostate cancer	0.000137	0.000746	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP17A1—prostate cancer	0.000136	0.000745	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP2C19—prostate cancer	0.000136	0.000741	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—AKR1C3—prostate cancer	0.000133	0.000726	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTT1—prostate cancer	0.000132	0.000723	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ACHE—prostate cancer	0.000132	0.000723	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PRKACB—prostate cancer	0.000132	0.000722	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP2A6—prostate cancer	0.000131	0.000715	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP17A1—prostate cancer	0.000131	0.000714	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—NCOA2—prostate cancer	0.00013	0.00071	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—AKR1C3—prostate cancer	0.000127	0.000696	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PRKACB—prostate cancer	0.000127	0.000692	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP17A1—prostate cancer	0.000125	0.000685	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—NCOA2—prostate cancer	0.000125	0.000681	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—SLC5A5—prostate cancer	0.000124	0.000677	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP2E1—prostate cancer	0.000121	0.000662	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—NQO1—prostate cancer	0.00012	0.000654	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NCOA2—prostate cancer	0.000119	0.000653	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—SLC5A5—prostate cancer	0.000119	0.000649	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—TH—prostate cancer	0.000118	0.000645	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP3A4—prostate cancer	0.000117	0.000638	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP2E1—prostate cancer	0.000116	0.000634	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—NQO1—prostate cancer	0.000115	0.000627	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP1B1—prostate cancer	0.000115	0.000627	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—SLC5A5—prostate cancer	0.000114	0.000623	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—TH—prostate cancer	0.000113	0.000618	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP3A4—prostate cancer	0.000112	0.000612	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP2E1—prostate cancer	0.000111	0.000608	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GGT1—prostate cancer	0.000111	0.000607	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP1B1—prostate cancer	0.00011	0.000601	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NQO1—prostate cancer	0.00011	0.000601	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—NCOA1—prostate cancer	0.00011	0.000598	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—TH—prostate cancer	0.000108	0.000593	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP19A1—prostate cancer	0.000108	0.00059	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP3A4—prostate cancer	0.000107	0.000586	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GGT1—prostate cancer	0.000107	0.000582	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP1B1—prostate cancer	0.000106	0.000576	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—NCOA1—prostate cancer	0.000105	0.000574	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—RXRA—prostate cancer	0.000104	0.000569	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP19A1—prostate cancer	0.000103	0.000565	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GGT1—prostate cancer	0.000102	0.000558	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NCOA1—prostate cancer	0.000101	0.00055	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—COMT—prostate cancer	0.0001	0.000548	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—RXRA—prostate cancer	9.99e-05	0.000546	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTP1—prostate cancer	9.99e-05	0.000546	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP19A1—prostate cancer	9.92e-05	0.000542	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ITPR1—prostate cancer	9.83e-05	0.000537	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—COMT—prostate cancer	9.62e-05	0.000526	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTP1—prostate cancer	9.57e-05	0.000523	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—RXRA—prostate cancer	9.57e-05	0.000523	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ITPR1—prostate cancer	9.42e-05	0.000515	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—TYMS—prostate cancer	9.28e-05	0.000507	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—COMT—prostate cancer	9.22e-05	0.000504	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTP1—prostate cancer	9.18e-05	0.000501	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—GSTM1—prostate cancer	9.18e-05	0.000501	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ITPR1—prostate cancer	9.03e-05	0.000493	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—LPL—prostate cancer	9.01e-05	0.000492	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—TYMS—prostate cancer	8.9e-05	0.000486	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—GSTM1—prostate cancer	8.8e-05	0.000481	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CYP1A1—prostate cancer	8.7e-05	0.000475	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—LPL—prostate cancer	8.64e-05	0.000472	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—ERCC2—prostate cancer	8.63e-05	0.000471	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—TYMS—prostate cancer	8.53e-05	0.000466	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—GSTM1—prostate cancer	8.43e-05	0.000461	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CYP1A1—prostate cancer	8.34e-05	0.000456	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—LPL—prostate cancer	8.28e-05	0.000452	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—ERCC2—prostate cancer	8.27e-05	0.000452	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—MTHFR—prostate cancer	8.11e-05	0.000443	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CYP1A1—prostate cancer	8e-05	0.000437	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PPARA—prostate cancer	7.96e-05	0.000435	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—ERCC2—prostate cancer	7.93e-05	0.000433	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—MTHFR—prostate cancer	7.78e-05	0.000425	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PPARA—prostate cancer	7.63e-05	0.000417	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CAV1—prostate cancer	7.48e-05	0.000409	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—MTHFR—prostate cancer	7.45e-05	0.000407	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PPARA—prostate cancer	7.31e-05	0.0004	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CAV1—prostate cancer	7.17e-05	0.000392	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CAV1—prostate cancer	6.88e-05	0.000376	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PIK3CG—prostate cancer	6.81e-05	0.000372	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PIK3CG—prostate cancer	6.53e-05	0.000357	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—INS—prostate cancer	6.45e-05	0.000352	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—CREBBP—prostate cancer	6.32e-05	0.000345	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PIK3CG—prostate cancer	6.26e-05	0.000342	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—INS—prostate cancer	6.18e-05	0.000338	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—CREBBP—prostate cancer	6.06e-05	0.000331	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PIK3CD—prostate cancer	5.99e-05	0.000327	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—INS—prostate cancer	5.93e-05	0.000324	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—CREBBP—prostate cancer	5.81e-05	0.000317	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PIK3CD—prostate cancer	5.74e-05	0.000314	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—NOS3—prostate cancer	5.66e-05	0.000309	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PIK3CD—prostate cancer	5.51e-05	0.000301	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—NOS3—prostate cancer	5.42e-05	0.000296	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PIK3CB—prostate cancer	5.22e-05	0.000285	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—NOS3—prostate cancer	5.2e-05	0.000284	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PTGS2—prostate cancer	5.17e-05	0.000283	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PIK3CB—prostate cancer	5.01e-05	0.000273	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PTGS2—prostate cancer	4.96e-05	0.000271	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PIK3CB—prostate cancer	4.8e-05	0.000262	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PTGS2—prostate cancer	4.76e-05	0.00026	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PTEN—prostate cancer	4.51e-05	0.000247	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PTEN—prostate cancer	4.33e-05	0.000236	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—EP300—prostate cancer	4.3e-05	0.000235	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PTEN—prostate cancer	4.15e-05	0.000227	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—EP300—prostate cancer	4.12e-05	0.000225	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—EP300—prostate cancer	3.95e-05	0.000216	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—PIK3CA—prostate cancer	3.18e-05	0.000174	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—PIK3CA—prostate cancer	3.05e-05	0.000167	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—PIK3CA—prostate cancer	2.93e-05	0.00016	CbGpPWpGaD
Methyclothiazide—CA4—Metabolism—AKT1—prostate cancer	2.6e-05	0.000142	CbGpPWpGaD
Methyclothiazide—CA2—Metabolism—AKT1—prostate cancer	2.49e-05	0.000136	CbGpPWpGaD
Methyclothiazide—CA1—Metabolism—AKT1—prostate cancer	2.39e-05	0.000131	CbGpPWpGaD
